Sath Shukla Sells 155,333 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla sold 155,333 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total value of $121,159.74. Following the transaction, the chief executive officer now owns 1,736,883 shares of the company’s stock, valued at approximately $1,354,768.74. This represents a 8.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Spero Therapeutics Price Performance

Shares of NASDAQ:SPRO opened at $0.86 on Friday. The firm has a market capitalization of $47.07 million, a PE ratio of 12.33 and a beta of 0.61. Spero Therapeutics, Inc. has a 1 year low of $0.74 and a 1 year high of $1.89. The firm’s 50-day moving average is $0.99 and its two-hundred day moving average is $1.19.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on SPRO shares. TD Cowen reaffirmed a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th. Evercore ISI cut shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a research report on Friday, December 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Spero Therapeutics in a research note on Thursday, January 30th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.